Table 2 Questionnaire survey depicting long-term outcomes in women undergoing local anaesthetic thermal balloon endometrial ablation (LA-Thermachoice) between 2001 and 2011
Variable | Varma et al. [9] | |
|---|---|---|
2001–2005 | 2001–2011 | |
Up to 3-year f/up | Up to 11-year f/up | |
Response rate | n = 88 (86 %) | n = 190 (78 %)a |
Mean follow-up time, months | 30 | 62 |
Range | 12–54 | 12–134 |
SD | 13 | 42 |
Periods at review | ||
Amenorrhoea | 27 (29 %) | 106 (56 %)b |
Lighter | 51 (55 %) | 75 (39 %) |
No change or worse | 15 (16 %) | 9 (5 %) |
Length of bleeding at review, n = 188 | ||
No bleeding | 106 (56 %) | |
<3 days | 26 (14 %) | |
3–5 days | 27 (14 %) | |
6–7 days | 16 (9 %) | |
8–10 days | 6 (3 %) | |
>10 days | 7 (4 %) | |
Dysmenorrhoea at review | ||
Less pain or no pain | 64 (69 %) | 167 (86 %) |
No change | 11 (12 %) | 18 (9 %) |
Worsening | 18 (19 %) | 10 (5 %) |
Benefit maintained over time, n = 185 | ||
Yes | 149 (81 %) | |
No | 36 (19 %) | |
Further treatment (repeat ablation, drugs, LNG-IUS or hysterectomy), n = 187 | ||
No | 83 (81 %) | 166 (89 %) |
Yes | 19 (19 %) | 21 (11 %) |
Reason for further treatment, n = 21 | ||
Bleeding | 6 (29 %) | |
Pain | 8 (38 %) | |
Both | 7 (33 %) | |
All types of further treatment | ||
No further treatment | 74 (73 %) | 156 (82 %) |
LNG-IUS | 3 (3 %) | 4 (2 %) |
Drugs (including HRT) | 9 (9 %) | 9 (5 %) |
Repeat endometrial ablation | 2 (2 %) | 1 (0 %) |
Hysterectomyc | 14(14 %) | 20 (11 %) |
Satisfaction, n = 186 | ||
Very satisfied or satisfied | 78 (76 %) | 161 (86 %) |
Dissatisfied | 24 (24 %) | 25 (14 %) |